Drug intelligence / Profile preview

VT400X

Development stage: Preclinical
Lead developer: Vigeo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VT400X is a preclinical-stage monoclonal antibody developed by Vigeo Therapeutics for the treatment of various cancers. It specifically targets PRSS2 (Serine protease 2), a protein often overexpressed in the tumor microenvironment that promotes tumor progression, metastasis, and immune evasion. By inhibiting PRSS2, VT400X aims to disrupt these pro-tumorigenic pathways and enhance anti-tumor immune responses. The drug is part of Vigeo's pipeline focusing on novel targets within the tumor microenvironment to overcome resistance to current therapies.

Targets

CD47 (Cluster of Differentiation 47)CD36 (CD36 antigen)

Beyond the preview

Go deeper on VT400X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT400X.

Explore the full profile